Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban
Galli, M.; Vassanelli, C.
Italian Heart Journal. Suppl Official Journal of the Italian Federation of Cardiology 2(10): 1127-1129
2001
ISSN/ISBN: 1129-4728 PMID: 11723619 Document Number: 540351
Document emailed within 1 workday
Related Documents
Gilbert, R.E. 2001: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes New England Journal of Medicine 345(21): 1574; Author Reply 1574-1575Cohen, M. 2000: Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes Journal of Invasive Cardiology 12 Suppl E: E5
Quinn, M.J.; Moliterno, D.J. 2002: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes Minerva Cardioangiologica 50(5): 547-553
Caputo, R.P.; Giambartolomei, A.; Simons, A.; Reger, M.; Wagner, S.; Esente, P. 2001: Adjunctive therapies in the cath lab. use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia Journal of Invasive Cardiology 13(9): 657-660
Boden, W.E. 2003: Interpretation of new treatment guidelines for non-ST-segment elevation acute coronary syndromes: "ischemia-guided" versus "early invasive" strategies Minerva Cardioangiologica 51(5): 447-461
Kassam, S.; Cantor, W.J.; Patel, D.; Gilchrist, I.C.; Winegard, L.D.; Rea, M.E.; Bowman, K.A.; Chisholm, R.J.; Strauss, B.H. 2004: Radial versus femoral access for rescue percutaneous coronary intervention with adjuvant glycoprotein IIb/IIIa inhibitor use Canadian Journal of Cardiology 20(14): 1439-1442
White, H.D. 2000: Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies? Journal of Invasive Cardiology 12 Suppl A: 6a
Zimarino, M.; De Caterina, R. 2004: Glycoprotein IIb-IIIa antagonists in non-ST elevation acute coronary syndromes and percutaneous interventions: from pharmacology to individual patient's therapy: part 1: the evidence of benefit Journal of Cardiovascular Pharmacology 43(3): 325-332
Hitzeman, N. 2007: Early invasive therapy or conservative management for unstable angina or NSTEMI? American Family Physician 75(1): 47-49
Hermanides, R.S.; Ottervanger, J.P.; ten Berg, J.M.; Gosselink, A.T.M.; van Houwelingen, G.; Dambrink, J.-H.E.; Stella, P.R.; Hamm, C.; van 't Hof, A.W.J. 2012: Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score Journal of Invasive Cardiology 24(3): 84-89
Rübsamen, K.; Hornberger, W.; Kirchengast, M. 1995: Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857 Thrombosis and Haemostasis 74(5): 1353-1360
Subbarao, V.D.; Phillips, J.; Stouffer, G.A. 1999: Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease American Journal of the Medical Sciences 318(2): 107-114
Chan, A.W.; Ross, J. 1997: Management of unstable coronary syndromes in patients with previous coronary artery bypass grafts following coronary angiography Clinical and Investigative Medicine. Medecine Clinique et Experimentale 20(5): 320-326
Szyguła-Jurkiewicz, B.; Wilczek, K.; Przybylski, R.; Pacholewicz, J.; Trzeciak, Pław.; Styn, T.; Zembala, M.; Poloński, L. 2004: Percutaneous and surgical revascularization in acute coronary syndromes without persistent ST segment elevation. One-year outcome of 361 patients assigned to early invasive strategy Przeglad Lekarski 61(12): 1295-1300
Kereiakes, D.J.; Kleiman, N.; Ferguson, J.J.; Runyon, J.P.; Broderick, T.M.; Higby, N.A.; Martin, L.H.; Hantsbarger, G.; McDonald, S.; Anders, R.J. 1997: Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment Circulation 96(4): 1117-1121
Cervinka, P. 1998: Clinical use of glycoprotein IIb/IIIa receptor blockers in invasive cardiology Vnitrni Lekarstvi 44(7): 439-443
Nishida, M.; Matsuno, H.; Kozawa, O.; Ueshima, S.; Matsuo, O.; Collen, D.; Uematsu, T. 2000: tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor Journal of Cardiovascular Pharmacology 36(6): 770-775
Gratsianskiĭ, N.A.; Esenbaeva, Z.M.; Zimin, I.V.; Kuznetsova, G.V.; Miseiuk, N.K. 1979: Results of prospective studies of patients with unstable angina pectoris treated by conservative methods Kardiologiia 19(8): 73-77
Platelet Receptor Inhibition, I.Ischemic Syndrome Management Study Investigators 1998: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina New England Journal of Medicine 338(21): 1498-1505
Maseri, A.; Rebuzzi, A.G.; Cianflone, D. 1997: Need for a composite risk stratification of patients with unstable coronary syndromes tailored to clinical practice Circulation 96(12): 4141-4142